Research
Energy balance
Future research should prioritize mechanistic human studies, real-world cardiovascular outcomes, and equity in drug access.
Practitioners and researchers should advocate for studies that address these areas to improve understanding and access to treatments.
StrongSupportsmedium confidence
Future research should prioritize mechanistic human studies, real-world cardiovascular outcomes, and equity in drug access.
Why this rating
The review synthesizes findings and suggests future directions.
Source
Biochemical and Pharmacological Mechanisms of GLP-1 and Dual Agonists: Implications for Glycemic Control and Cardiovascular Risk Reduction — A Review
Akter Sraboni et al. · Journal of Biochemistry Pharmacology and Public Health · 2026
DOI 10.64907/xkmf.v4.i1.jbpph.1
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists and dual incretin agonists provide clinically significant benefits in weight reduction, blood pressure modulation, lipid profile improvement, and cardiovascular risk mitigation.Strong
- Dual agonists provide additive and potentially synergistic metabolic benefits through complementary receptor activation.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →